Three Healthcare Stocks With Compelling Dividend Yields And Growth Rates

Published Wed, 16 Apr 2014 23:00 CET by DividendYields.org

The healthcare sector offers one of the best opportunities for investors. This is because health is not a luxury, and for some people it is a constant expense in their budgets.
Over the years, several companies have joined the market in different capacities and with various distinct target markets. While biotechnology companies are considered high reward speculative opportunities, large drug manufacturers like U.S.A’s Johnson & Johnson (NYSE: JNJ) and U.K’s GlaxoSmithKline (NYSE: GSK) offer stability and continuous payout in terms of dividends.
Over the last few years these two, along with Baxter International (NYSE: BAX), have shown resilience in their quest to grow dividends and maintain compelling yields. Now, these three form some of the most attractive dividend stocks in the healthcare sector.

Div Yield Div Growth (5 Yrs) Payout Ratio Exp Earnings Growth (1 yr) Exp Earnings Growth (5 yrs)
Johnson & Johnson 2.66% 7.49% 54% 7.72% 5.96%
GlaxoSmithKline 5.73% 4.23% 66% 9.26% 9.30%
Baxter International 2.67% 15.47% 52% 6.80% 7.45%
Johnson & Johnson
The U.S-based drug manufacturer offers investors a 2.66% dividend yield, based on its current stock price of $99.20 per share. This is after cruising 22.39% over the last 12 months.
Johnson & Johnson enjoys a wide economic moat, is well diversified and offers several products related to human health and hygiene. This provides the stability needed for dividend stocks, to prevent earnings and dividends from falling massively when one business segment performs poorly.
The company’s payout ratio of 54% is within the recommended threshold of not more than 60%, which means there is enough margin of safety to maintain a healthy dividend.
Johnson & Johnson earnings are expected to grow by 7.72% over the next 12 months, and at a compound annual growth rate “CAGR” of 5.96% over the next five years. In this case, the company’s expected 7.49% dividend growth rate for the next five years implies that, at some point, it might have to increase the payout ratio.

GlaxoSmithKline
GlaxoSmithKline is probably the most attractive dividend stock in the healthcare sector. The company offers compelling dividend yield of 5.73% and almost unmatched earnings growth rates for the next five years at 9.30%. Based on these figures, the company’s dividend yield is expected to grow by 4.23%.
GlaxoSmithKline earnings per share are expected to grow by 9.26% for the next one year.
Now, based on the company’s projected dividend growth rate compared to earnings growth rate, it appears as though the payout ratio could be cut significantly. This is positive for the company as it currently pays out 66% of its earnings as dividend, which is slightly above the recommended maximum rate.
Unlike Johnson & Johnson, GlaxoSmithKline’s price is only up about 5.95% over the last twelve months. However, its huge dividend yield has been a terrific example of how dividend stocks could differ from income stocks.

Baxter International
This is the smallest of the three healthcare giants. However, its market cap of more than $40 billion makes it a giant in its own respect. Therefore, it offers significant financial stability to investors.
When compared with is counterparts, Baxter International offers the best option for investors looking to reap more in term of dividends over the next five years. Its dividend is expected to grow by an average of 15.47% over the next five years. This means that the current quarterly dividend per share of $0.49 could rise to $0.56 next year.
The company’s payout ratio of 52% is also the best among the three companies. Baxter International operates in a slightly different industry from its two counterparts.
The medical instruments and supplies provider is also expected to enjoy significant earnings growth over the next five years at about 7.45% CAGR, which again is a clear signal for sustainable dividend payments.

Conclusion

12-Month Stock Price Graph
While GlaxoSmithKline offers the best dividend yield at current prices, Baxter International appears to be a compelling candidate for that tag in the coming years.
On the other hand, Johnson & Johnson enjoys wide economic moat and the best 12-month returns for those who might consider offloading some holding for cash, compared to GlaxoSmithKline’s 5.95%, and Baxter’s 3.47%.
Overall, they all appear to be some excellent dividend stocks to consider in 2014.


Stock name Dividend Yield
Glaxosmithkline 4.94
Johnson & Johnson 2.69
Baxter International 1.04

Articles featuring Glaxosmithkline (GSK):

5%+ Dividend Yield Portfolio: Ignore The Political Circus (Sep 2018 Review)

Outlook If you mix your politics with your investment decisions, you’re making a big mistake. - Warren Buffett Politics dominates the headlines these days (even in the financial press)… and how could it not with the circus on display. However, allowing your political views to shade your investment decisions is a sure loser. In fact, even following the political headlines too closely, even when they touch on the economy (e.g. the many threatened or real government shutdowns... Read more

First Quarterly Update - Steve's Dividend Portfolio And Strategy For Replacing My Salary With Dividend Income

Welcome to the First Quarterly update in my series for replacing my salary with dividend income. In the initial article, I outlined my portfolio strategy for replacing one of our salaries when my wife and I retire which is comprised of individual securities and ETFs. It's been three months since this article was released and I have some updates to share. The current state of the portfolio Individual Securities Quarter Month 1 Month 2 Month 3 Ticker Dividend... Read more

5%+ Dividend Yield Portfolio: Foreign Markets Disappointing You Again? (August 2018 Review)

Outlook Call it the pain of international diversification for 2018. With a significant divergence between US and international equities, the cost with holding DM and EM stocks has been significant. The differential between EM and US growth indices is over 25%. - Mark Rzepczynski There's just no way to sugar coat it, owning foreign stocks in 2018 (just like in 2017) has a real drag on returns. And there's plenty of pain to go around with both developed and emerging markets... Read more

5%+ Dividend Yield Portfolio: Sticking To The Plan (July 2018 Review)

Outlook "Nothing so undermines your financial judgement as the sight of your neighbor getting rich. - J.P. Morgan For fundamentals driven investors with a value tilt like me, July was likely a solid month with decent gains in holdings value. However, most value focused investors probably struggled to match the blazing +3.7% of the S&P 500. Despite the late month implosions of Facebook (FB) and Twitter (TWTR), this is still very much a growth/momentum driven market with large... Read more

GlaxoSmithKline: Dividend Safe For Now

We have been long GlaxoSmithKline (GSK) for many months now and our cost (excluding reinvested dividends) is around the $35.50 level. With shares now trading north of $41 per share, we still see upside so will be remaining long for the time being. It seemed at the time that shares were under pressure due to the viability or lack thereof of the dividend. Value and dividend growth investors have bought aggressively since the March lows which has resulted in a 14%+ increase in the share price... Read more